We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01322165
First Posted: March 24, 2011
Last Update Posted: December 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party):
National Heart, Lung, and Blood Institute (NHLBI)
March 22, 2011
March 24, 2011
December 20, 2016
November 2007
September 2015   (Final data collection date for primary outcome measure)
Thoracic aortic aneurysms and dissections and their associated surgical interventions [ Time Frame: bi-annual ]
Not Provided
Complete list of historical versions of study NCT01322165 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) was initiated in 2006 by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). GenTAC established a registry of 3706 patients with genetic conditions that may be related to thoracic aortic aneurysms and collected medical data and biologic samples. The study ended in September 2016. Data and samples are available from NHLBI and requests should be made to BioLINCC. See the NHLBI website for more information: https://www.nhlbi.nih.gov/research/resources/gentac/.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
If a blood specimen is obtained, it is separated and stored as plasma, viable cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA.
Non-Probability Sample
The cohort consists of patients with conditions related to genetically-induced thoracic aortic aneurysms.
  • Marfan Syndrome
  • Turner Syndrome
  • Ehlers-Danlos Syndrome
  • Loeys-Dietz Syndrome
  • FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation
  • Bicuspid Aortic Valve Without Known Family History
  • Bicuspid Aortic Valve With Family History
  • Bicuspid Aortic Valve With Coarctation
  • Familial Thoracic Aortic Aneurysm and Dissections
  • Shprintzen-Goldberg Syndrome
  • Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo
  • Other Congenital Heart Disease
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3706
September 2016
September 2015   (Final data collection date for primary outcome measure)

Eligible subjects must have one of the conditions listed below and be enrolled in-person at one of the participating clinical centers.Contact the study coordinator at the location nearest you for more information about participation.

  • Marfan syndrome
  • Turner syndrome
  • Ehlers-Danlos syndrome
  • Loeys-Dietz syndrome
  • FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 genetic mutation
  • Bicuspid aortic valve without known family history
  • Bicuspid aortic valve with family history
  • Bicuspid aortic valve with coarctation
  • Familial Thoracic Aortic Aneurysm and DissectionsYes
  • Shprintzen-Goldberg syndrome
  • Other aneurysms and dissections of the thoracic aorta not due to trauma, <50yo
  • Other congenital heart disease (e.g., Tetralogy of Fallot, coarctation)

Exclusion Criteria:

  • Inability of the patient, parent or guardian to give consent.
  • Unwillingness to provide a blood or buccal specimen.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01322165
1438
268201000048C-5-0-1 ( U.S. NIH Grant/Contract )
N01HV68199-7-0-1 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
National Heart, Lung, and Blood Institute (NHLBI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Study Director: Barbara Kroner, PhD, MPH RTI International
Principal Investigator: Richard Devereux, MD The New York Presbyterian Hospital-Weill Cornell Medical Center
Principal Investigator: William Ravekes, M.D. Johns Hopkins University
Principal Investigator: Reed E. Pyeritz, M.D., Ph.D. University of Pennsylvania
Principal Investigator: Dianna M. Milewicz, M.D. Ph.D. University of Texas Medical School at Houston
Principal Investigator: Scott A. LeMaire, M.D. Baylor College of Medicine
Principal Investigator: Cheryl L. Maslen, Ph.D. Oregon Health and Science University
Principal Investigator: Ralph Shohet, MD University of Hawaii
Principal Investigator: Jennifer Habashi, MD Johns Hopkins University
Principal Investigator: Federico M. Asch, MD,FACC,FASE Medstar
Study Chair: Kim Eagle, M.D. University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)
December 2016
To Top